Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Financial Results
    • Dr Reddys Q2 revenue...

    Dr Reddys Q2 revenue up 26.4 pc to Rs 4801 crore

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-11-03T09:30:13+05:30  |  Updated On 16 Aug 2021 5:47 AM GMT

    Revenue in the second quarter stood at Rs 4,800.9 crore as against Rs 3,797.8 crore in the year-ago period, an increase of 26.41 per cent, Dr Reddy's (Dr Reddys) added.


    New Delhi: Dr Reddy's Laboratories on Friday reported over two-fold jump in consolidated net profit to Rs 1,092.5 crore for the second quarter ended September 30, 2019. The company had posted a profit of Rs 503.80 crore for the year-ago period, Dr Reddy's said in a regulatory filing.


    The net tax for the quarter has a benefit of Rs 330 crore due to recognition of deferred tax assets of Rs 520 crore, primarily related to the MAT credit, it said.


    Revenue in the second quarter stood at Rs 4,800.9 crore as against Rs 3,797.8 crore in the year-ago period, an increase of 26.41 per cent, it added.


    Company's Co-Chairman and MD GV Prasad said the performance across the businesses and strong cash generation during the quarter are pleasing.


    "We are progressing well in execution of our strategy and in our transformation journey on quality and efficiency," he added.


    Global generics segment revenues were at Rs 3,280 crore, up 7 per cent from the same quarter last fiscal, primarily driven by Europe, emerging markets and India, the company said.


    Revenues from North America were flat at Rs 1,430 crore while that from Europe were at Rs 280 crore. Revenues from India stood at Rs 750 crore and emerging markets at Rs 830 crore, it added.


    Read Also: Dr Reddys Srikakulam plant gets 4 USFDA observations


    Dr Reddy's said its pharmaceutical services and active ingredients revenue was at Rs 710 crore, up 18 per cent from the corresponding period last fiscal.


    Proprietary products segment clocked a revenue of Rs 740 crore, including Rs 720 crore towards licence fee for selling the US and select territory rights for two of neurology brands namely ZEMBRACE SYMTOUCH (sumatriptan injection) 3 mg and TOSYMRATM (sumatriptan nasal spray) 10 mg, to Upsher-Smith Laboratories, LLC, the company said.

    https://pubads.g.doubleclick.net/gampad/ads?iu=/21687779244/clinicalkey_video_ad&description_url=[placeholder]&tfcd=0&npa=0&sz=640x480&gdfp_req=1&output=vast&unviewed_position_start=1&env=vp&impl=s&correlator=

    Read Also: Dr Reddys gets CDSCO Committee recommendation for approval for additional indications of Desosumab

    Dr Reddy Dr Reddy Laboratories Dr Reddy's Dr Reddy's Laboratories Dr Reddy's Labs dr reddys profit dr reddys q2 dr reddys result dr reddys revenue GV Prasad Smith Labs sumatriptan injection TOSYMRATM ZEMBRACE SYMTOUCH 
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      X